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1 Acute aortic dissection (AD), intramural hematoma (IMH), and penetrating aortic ulcer (PAU) all have a similar clinical presentation and can transform into one another, indicating a similar underlying pathophysiology. 1 AD is characterized by the presence of an intimal flap dividing the aortic lumen into a false and true lumen. 2 Despite being considered pathological variants of AD, IMH, and PAU are not associated with an intimal flap. In fact, an IMH is thought to arise from the rupture of the vasa vasorum in the media of the aortic wall and is referred to as a hematoma contained within the vessel wall.
3,4
IMH is second to AD in prevalence, accounting for 10 to 20% of all AAS, 5 yet there are no clear guidelines regarding its optimal management. The Stanford classification for AD has been the foundation for clinical decision-making in the treatment of IMH and PAU. Type-A IMH/PAU are managed surgically whereas type-B IMH/PAU are medically managed with conversion to surgery in the event of rapid aortic dilatation, impending rupture, and frank rupture. 6,7 Nevertheless, this approach has been questioned by studies from Eastern countries. An unknown "Asian factor" has been invoked to explain the improved outcomes seen with medical management of type-A IMH in Japanese and Korean series. 3, 8 On the contrary, medical management has also been associated with an in-hospital mortality rate of 32%, questioning the effectiveness of an initial conservative therapy and reinforcing the concept that early surgical intervention may be warranted. 9 An IMH has the potential to regress completely but also poses a very real risk of catastrophic complications, including aneurysm progression, frank AD,
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Intramural hematoma (IMH) is a variant form of aortic dissection characterized by involvement of the aortic media without the presence of an overt intimal flap. Surgical extirpation is the standard of care for type-A IMH in the Western world. However, a conservative approach with anti-impulse therapy has been advocated especially in Japan as a viable alternative. Here, we report a case of an elderly male patient with a history of metastatic stage 4 renal cell carcinoma who was treated with anti-impulse therapy for an acute type-A IMH. Blood pressure stabilization and continuous monitoring resulted in complete resolution of the IMH within 6 days. This report illustrates how immediate medical management in patients with acute type-A IMH who are not surgical candidates can alleviate the progression or even lead to regression as early as 1 week after initiating anti-impulse therapy.
and aortic rupture. 5 It is this unpredictable natural progression of an IMH that confounds clinical decision-making. We present the case of a 70-year-old man with a history of stage 4 renal cell carcinoma (RCC), who was admitted for management of an acute type-A IMH. Medical management resulted in resolution of the AAS within 6 days, as confirmed by serial imaging.
Case Report
We report the case of a 70-year-old male patient with a history of stage 4 RCC with metastasis to the adrenal glands, lymph nodes, lungs, and skin being treated with cabozantinib, an inhibitor of the tyrosine-protein kinase Met (cMET) and the vascular endothelial growth factor 2 (VEGFR2) used to reduce tumor growth, metastasis, and angiogenesis. He presented to the emergency department with complaints of pressure, such as lower back pain, abdominal pain, and bloating. Also, shortness of breath (SOB) and hypoxia were noted. As part of the workup for SOB, an echocardiogram showed a mild decrease in left ventricular ejection fraction (43%) and a dilated ascending aorta measuring 3.9 cm with a possible flap, raising concern for a dissection. Computed tomography angiography (CTA) scan of the chest revealed the presence of an IMH involving the aortic root, ascending aorta, aortic arch, descending thoracic aorta, and upper abdominal aorta. The maximal ascending aorta diameter was 4.3 cm at the level of the main pulmonary artery (►Fig. 1). The patient's RCC had been stable as per the Oncology Team, and they deemed surgical repair of the type-A IMH appropriate if indicated. The risk of progression to rupture and subsequent death without intervention was estimated to be 40%. Vascular surgery deemed the patient unsuitable for endovascular aortic repair of the descending IMH. However, the cardiac surgical team chose to manage the patient conservatively. Continuous monitoring and anti-impulse therapy were instituted in the cardiothoracic intensive care unit. Initially, hydralazine and nicardipine drips were utilized to maintain systolic blood pressure below 120 mm Hg. Once this was achieved, the transition to oral labetalol and amlodipine was made. Follow-up CTA scan 6 days later demonstrated complete resolution of the acute IMH of the ascending aorta as well as a decrease in size from 4.3 to 3.3 cm with persistence of the descending IMH (►Fig. 2). Recommendation for continued medical therapy was made, and the patient was discharged home in satisfactory condition. He was seen in follow-up 2 months later with a normal-appearing ascending aorta and mild further enlargement of the descending aorta.
Discussion
IMH is described as a pathological variant of AD. IMH has an unpredictable natural history. The clinical presentation is similar to that of any other AAS, with pain being the predominant symptom. Nevertheless, IMH tends to be present in older patients and has a female predominance in contrast to classical AD. 4 As an IMH propagates, there is weakening of the aortic wall which may lead to aneurysmal dilation and as well as rupture, and fracture of the intima leading to overt dissection, a complication with an incidence of 12 to 47%. 5 The presence or absence of spontaneous regression/resolution directly impacts the decision between surgical and medical treatment. Acute type-A IMH is treated surgically, whereas type-B IMH in the absence of complications is treated with anti-impulse therapy and strict followup. 6 Conversely, this doctrine has been challenged by Asian studies that have shown good outcomes and resolution in medically treated patients with type-A IMH. 2, 13 Moizumi et al 14 found that among the patients in their study, more than 50% were safely treated with medical therapy alone without the development of an overt complication. They postulated that the lack of flow in the thrombosed lumen decreases the risk of conversion to rupture. Our patient presented with a symptomatic acute type-A IMH, and generally, these patients are treated surgically at our institution. However, the IMH developed in the context of a patient with stage 4 RCC with multiple metastases in the lung, adrenal glands, lymph nodes, and skin, findings which portend a poor prognosis with survival rates at 5 years of 8%. 15 We felt aggressive surgical therapy was inappropriate. A medical management strategy with strict surveillance for life-threatening complications was adopted and proved fruitful. The uniqueness of this case lies in the complete regression of the ascending aortic IMH in a short period, thereby decreasing the risk of rupture or overt dissection by reducing the elevated shearing forces on the aortic wall. To the best of our knowledge, regression of an IMH has been described as early as 1 month, 5 with one case report demonstrating rapid regression in less than 24 hours in another patient also with a history of RCC 16 (►Table 1). Our group encourages surgical approach for patients with acute type-A IMH. 4 However, this case highlights the role of medical management in a subset of patients in whom a surgical approach might not be best. This case also demonstrates that adequate control of systolic blood pressure can engender regression of a type-A IMH as early as 6 days and thus reduce the risk of immediate catastrophic complications.
Conclusion
Anti-impulse therapy for acute type-A IMH is a valuable alternative for patients in whom the potential risk of an open surgical approach outweighs the benefits. Despite the Western consensus that type-A AAS should be managed surgically, autonomous regression is still one possible outcome. This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
